tradingkey.logo

Obesity drugmaker Novo Nordisk cuts 2025 sales growth, operating profit outlook

ReutersJul 29, 2025 11:04 AM

- Obesity drugmaker Novo Nordisk NOVOb.CO warned on Tuesday that full-year sales and operating proft would grow less than previously expected, marking its second forecast cut of 2025.

The maker of weight-loss drug Wegovy is struggling to convince investors it can remain competitive in the obesity drug boom against U.S. rival Eli Lilly LLY.N. Novo shares have fallen sharply over the past year.

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI